In parallel, the historical success of PARP inhibition in BRCA-mutant breast and ovarian cancers underscores how targeting single-strand break repair can be lethal for cells in which HR is already compromised, a principle now applied to PCa, with a growing list of DDR defects [47]. The gene discussed is PARP1; the disease is ovarian cancer.